Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
February 22, 2024 10:10 ET
|
Imugene Limited
Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, highlighted recent progress across the company's immuno-oncology portfolio.
Hyloris annonce une date potentielle d’enregistrement pour Maxigesic® IV aux Etats-Unis
May 02, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
- La date limite d’enregistrement a été fixée au 17 octobre 2023 par la Food & Drug Administration des États-Unis. - Le partenaire commercial exclusif de Maxigesic® IV aux États-Unis est Hikma...
Hyloris announces potential registration date for Maxigesic® IV in the US
May 02, 2023 01:00 ET
|
Hyloris Pharmaceuticals SA
PDUFA goal date set for 17 October 2023 by U.S. Food & Drug AdministrationExclusive commercial partner for Maxigesic® IV in the U.S. is Hikma Pharmaceuticals, a leading supplier of complex,...
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
January 26, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 14, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
August 01, 2012 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...